Innovent Biologics, Inc. (1801)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 07, 2025

$4.52

P/E Ratio

N/A

Market Cap

$7.44B

Loading...
Description

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.

Metrics

Overview

  • HQSuzhou, JS
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • Ticker1801
  • Price$4.521569-0.39%

Trading Information

  • Market cap$7.44B
  • Float92.46%
  • Average Daily Volume (1m)5,823,371
  • Average Daily Volume (3m)11,718,375
  • EPS-$0.73

Company

  • Revenue$6.86B
  • Rev growth (1yr)29.43%
  • Net incomeN/A
  • Gross marginN/A
  • EBITDA margin-10.05%
  • EBITDAN/A
  • EVN/A
  • EV/Revenue8.54
  • P/EN/A
  • P/S7.10
  • P/B4.31
Documents